CVS
CVS Health
$101.30
▲ 3.0%Updated Today 7:15 PM ET
▲ Up 47.1% over the last 12 months
Market Cap
$125.45B
P/E
42.47x
Forward P/E (est.)
60.67x
ROE
3.9%
Revenue Growth
7.6%
EPS Growth
-46.0%
Profit Margin
0.7%
FCF Yield
9.9%
Debt / Equity
0.86x
ROIC
3.0%
Interest Coverage
1.75x
Current Ratio
0.87x
Dividend Yield
2.6%
Implied Growth (rev. DCF)
2.6%
Rating Score
32/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CVS's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CVS trades near $101.30, above its 50-day average ($88.74) and 200-day average ($80.22). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 71 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. CVS's is $2.44 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CVS found buyers near $89.42 (support) and sellers near $102.77 (resistance); its 52-week range is $58.50–$102.77. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 2.6× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
CVS Health (CVS) is a large-cap company in the Health Care Services industry, part of the Health Care sector of the S&P 500, with a market value around $125.45B.
In its latest reported year it generated about $402.07B in revenue and $1.77B in net profit.
Our model rates CVS Weak (32/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
8.3%
Revenue moved from $292.11B in 2021 to $402.07B in 2025, a 8.3% compound annual growth rate. The most recent year grew a steady 7.6% year over year. Slower, mature growth is common for established businesses.
Gross Margin
13.9%
Operating Margin
1.2%
Net Margin
0.4%
ROE
3.9%
CVS Health keeps about 0.7% of each sales dollar as net profit, with a 13.9% gross margin and 1.2% operating margin. Return on equity is 3.9% and return on invested capital about 3.0%. Thin margins leave less cushion if costs rise.
Total Debt
$69.05B
Net Debt
$59.51B
Net Debt / EBITDA
12.77x
Debt / Equity
0.86x
Leverage: debt-to-equity is 0.9x, and operating profit covers interest about 1.8x, with a current ratio of 0.9x. That is a moderate, manageable debt load for most businesses. It carries roughly $69.05B of total debt against $9.54B of cash.
Operating CF
$10.64B
Free Cash Flow
$7.81B
FCF Margin
1.9%
In the latest year CVS Health produced about $10.64B of operating cash flow and $7.81B of free cash flow after capital spending. That is a free-cash-flow yield of about 9.9% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
42.47x
P/S
0.32x
P/B
1.31x
EV / EBITDA
20.29x
CVS trades at 42.5x trailing earnings (about 60.7x on estimated forward earnings), 0.3x sales, and 1.3x book value. Reverse-engineering today's price implies the market expects roughly 2.6% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How CVS stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), CVS ranks #53 of 59 by our overall rating. It trades at a premium versus the sector on earnings (42.5x P/E vs. 25.4x median) with a lower return on equity (3.9% vs. 14.9%) and slower revenue growth (7.6% vs. 7.9%).
P/E vs sector
42.5x
median 25.4x
ROE vs sector
3.9%
median 14.9%
Growth vs sector
7.6%
median 7.9%
Sector rank
#53
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$347.26 – $583.39
vs. $101.30 today · expected CAGR 28% – 42%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $434.23B | $468.97B | $506.49B | $547.01B | $590.77B |
| Net income | $13.03B | $14.07B | $15.19B | $16.41B | $17.72B |
| EPS | $10.21 | $11.03 | $11.91 | $12.86 | $13.89 |
| Share price (low) | $255.25 | $275.66 | $297.72 | $321.54 | $347.26 |
| Share price (high) | $428.81 | $463.12 | $500.17 | $540.18 | $583.39 |
| CAGR (low–high) | 152% / 323% | 65% / 114% | 43% / 70% | 33% / 52% | 28% / 42% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CVS:
- Healthy free-cash-flow yield (~9.9%) funds buybacks and dividends.
- Pays a 2.6% dividend on top of any price gains.
The case against CVS:
- Thin net margins (0.7%) leave little room for error.
- Interest coverage is thin (1.8x), so debt costs bite.
- A rich 42.5x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (32/100).
Valuation risk — at 42.5x earnings, disappointing results could compress the multiple.
Margin risk — thin profitability (0.7%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: CVS Health is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 42.5x earnings, which our model scores Weak (32/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.